¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧ1998ÄêÃâÒßѧ£¨²©Ê¿£©
¼¶±ð: ²©Ê¿
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-20   

µÚËľüÒ½´óѧ1998ÄêÃâÒßѧ£¨²©Ê¿£©

µÚËľüÒ½´óѧ1998ÄêÃâÒßѧ£¨²©Ê¿£© SJ^ .#^)  
Pon 2! $  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© pvQw+jX  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© k/=J<?h0  
1.Co-stimulators (or co-stimulating molecules) BhLYLlXPY  
2.NK-kB ,h5\v WZ  
3.Immunoglobulin superfamily mMjY I1F  
4.antigen-presenting cell (APC) Yvs)H'n=  
5.death domain f}0(qN/G  
6.CCR and CXCR z 3fS+x:E{  
7.Lectin (or mitogen) b/5?)!I  
8.Clusters of differentiation, CD) s[NkPh9&  
9.B7 family >y"W(  
10.Cytotoxic T lymphocyte, CTL) $Lv,e\]  
11.IL-15 and IL-15 receptor (IL-15R) d5fnJ*a>l  
12.MHC restriction !fZ\GOx  
13.Affinity-chromatography /T]2ZX>  
14.Cyctosprin A, CsA G)]'>m<y  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) wUW^ O  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© 7/a[;`i*!  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 *%7[{Loz  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ *9y)B|P^  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢á¹¹¼°Æäʶ±?¿¹Ô­µÄÌØµã¡£ iagl^(s  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© >0Y >T6!  
ÃâÒßѧרҵ£º I'HPy.PV  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ /17Qhex  
Ïû»¯ÄÚ¿Æ£º m~'!  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ ExeD3Zj  
ѪҺ²¡Ñ§×¨Òµ£º ztTj2M"  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
2+6=? ÕýÈ·´ð°¸:8
°´"Ctrl+Enter"Ö±½ÓÌá½»